JOURNAL OF CLINICAL PSYCHIATRY, cilt.69, sa.2, ss.274-285, 2008 (SCI-Expanded)
Background: Clozapine, despite its side-effect burden, has been considered to be the drug of choice for patients with schizophrenia whose psychotic symptoms fail to respond adequately to other antipsychotic drugs. There are conflicting data concerning the potential utility of olanzapine in treatment-resistant schizophrenia at doses beyond the 10- to 20-mg/day range that has proven to be effective for most nonrefractory patients with schizophrenia.